TICKERNERD
Menu
NUVBNUVBHealthcare · Biotechnology

NUVB Stock Forecast: Nuvation Bio, Inc. Price Predictions for 2026-2027

Last close, 18 Sept 2026
$5.85
−3.62% on the day

The 10 Wall Street analysts covering Nuvation Bio, Inc. hold a median 12-month price target of $13 — +113.7% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 60 of 100 as at 18 Sept 2026 — in the upper half.

Market cap
$2.1B
Ticker Nerd rank
60 / 100
Median analyst target
$13
Analysts covering
10
Revenue$31.7M+555.6% y/y
Operating income−$51.0M
Net income−$62.8M
Free cash flow−$43.2M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
−3.6%
1M
−15.9%
YTD
−34.7%
1Y
+84.5%
From 52W high
−38.7%
From 52W low
+94.4%
$3.01
$9.54
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

NUVB stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Nuvation Bio, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 18 Sept 2026
60 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Value
93
Momentum
80
Quality
77
Growth
75
Revisions
46
Volatility
44
Accruals
38
Size
35
Issuance
11

Value (93): The shares cost little relative to the profits and assets behind them — which can mean the market is too gloomy, or that the business really is in trouble.

Issuance (11): The company has been issuing shares or taking on financing, diluting existing holders.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

NUVB stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on NUVB, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$0.00$5.00$10.00$15.00$20.00Oct 25Jan 26Apr 26Jul 26NUVBHigh $21Median $13Low $7

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says10 analysts
9 Buy1 Hold0 Sell
Low $7Median $13High $21

The green dot is the last close — the median target sits +113.7% from it.

Recent analyst actionsNewest first

Of the 20 most recent actions, 3 moved their price target up and 1 moved it down.

DateFirmActionRatingTarget
16 Sept 2026CitizensReiteratesMarket Outperform$10
16 Sept 2026WedbushReiteratesOutperform$11
21 Aug 2026Cantor FitzgeraldInitiatesOverweight—
18 Aug 2026JP MorganInitiatesOverweight$13
7 Aug 2026RBC CapitalMaintainsOutperform—
7 Aug 2026RBC CapitalMaintainsOutperform$19 → $20
27 July 2026HC Wainwright & Co.MaintainsBuy$17 → $21
27 July 2026HC Wainwright & Co.MaintainsBuy—
23 July 2026WedbushReiteratesOutperform$11
23 July 2026WedbushReiteratesOutperform—
7 July 2026RBC CapitalMaintainsOutperform—
7 July 2026RBC CapitalMaintainsOutperform$20 → $19
7 July 2026Truist SecuritiesMaintainsBuy—
7 July 2026Truist SecuritiesMaintainsBuy$12 → $13
5 May 2026HC Wainwright & Co.ReiteratesBuy—
5 May 2026RBC CapitalReiteratesOutperform—
5 May 2026WedbushReiteratesOutperform—
16 Apr 2026WedbushReiteratesOutperform—
2 Apr 2026WedbushReiteratesOutperform—
27 Mar 2026WedbushReiteratesOutperform—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. NUVB appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Performance

NUVB vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 18 Sept 2026, Nuvation Bio, Inc. returned +84.5% against +16.3% for the S&P 500, dividends included.

NUVB vs S&P 500, last 12 monthsTotal return, rebased to 100
100150200250300Oct 25Jan 26Apr 26Jul 26NUVBS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

NUVB analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
Analysts raising
0
Analysts cutting
1
Fundamentals

Nuvation Bio, Inc. (NUVB) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
−10.1×

Cheaper than 93% of US stocks

Price / sales
12.5×

Cheaper than 12% of US stocks

Price / book
8.4×

Cheaper than 11% of US stocks

EV / EBITDA
−13.9×

Cheaper than 87% of US stocks

Growth & margins
Revenue growth (YoY)
555.6%

Higher than 98% of US stocks

Earnings growth (YoY)
555.6%

Higher than 96% of US stocks

Gross margin
70.1%

Higher than 83% of US stocks

Operating margin
−161.1%

Higher than 12% of US stocks

Net margin
−88.2%

Higher than 6% of US stocks

Returns & dividend
Return on equity
−47.8%

Higher than 22% of US stocks

Return on assets
−12.4%

Higher than 25% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

Nuvation Bio, Inc. (NUVB) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Nuvation Bio, Inc. has a market value of $2.1B and an enterprise value of $1.9B.

  • Revenue in the twelve months to 30 June 2026: $169.9M. The latest quarter grew 555.6% year on year.

  • Net income over the same four quarters: −$149.8M, a −88.2% net margin.

  • Diluted earnings per share, trailing twelve months: $−0.44.

  • Free cash flow in the twelve months to 30 June 2026: −$128.9M.

  • Shares outstanding: 349.8M.

  • Trailing P/E: −10.1×; forward P/E: −404.7× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Nuvation Bio, Inc. employs 305 people — $557K of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 18 Sept 2026

Data provided by Twelve Data

Peers

NUVB vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
NUVBNuvation Bio, Inc.$2.1B
60
ADMAADMA Biologics, Inc.$2.0B
43
VCELVericel Corp.$2.0B
94
URGNUroGen Pharma Ltd.$2.1B
82
SRPTSarepta Therapeutics, Inc.$2.1B
71
OCULOcular Therapeutix, Inc.$2.1B
35
TRVITrevi Therapeutics, Inc.$2.1B
53

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Nuvation Bio, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest NUVB news & analysis

Nuvation Bio Announces FDA Approval of Supplemental New Drug Application for IBTROZI® (taletrectinib) with Updated Duration of Response in TKI-Naïve Advanced ROS1-Positive Non-Small Cell Lung Cancer

PRNewsWire · 17 Sept 2026positive

The FDA approved a supplemental New Drug Application for Nuvation Bio's IBTROZI (taletrectinib), updating the label with a nearly 50-month median duration of response in TKI-naïve advanced ROS1-positive non-small cell lung cancer. Approval came about four months ahead of the PDUFA date, with no changes to safety labeling and no new safety signals identified.

Why it matters — The early FDA approval and updated efficacy data strengthen the commercial standing of Nuvation Bio's lead drug IBTROZI in the ROS1-positive NSCLC market.

Nuvation Bio Announces New Analyses Reinforcing the Durable, Consistent Efficacy of IBTROZI® (taletrectinib) Across Key Patient Subgroups in Advanced ROS1+ NSCLC at 2026 World Conference on Lung Cancer

PRNewsWire · 15 Sept 2026positive

Nuvation Bio announced new subgroup analyses from the pivotal TRUST-I and TRUST-II studies evaluating IBTROZI (taletrectinib) in advanced ROS1-positive non-small cell lung cancer. The analyses showed consistent, durable efficacy — including duration of response and progression-free survival — across CD74 and non-CD74 ROS1 fusion-partner subgroups and stable response rates among patients treated after prior chemotherapy. The findings were presented at the 2026 World Conference on Lung Cancer.

Why it matters — The new data reinforce IBTROZI's durable and consistent efficacy across key patient subgroups, supporting the drug's clinical profile for NUVB watchers.

Nuvation Bio Inc. (NUVB) Presents at Citigroup's Biopharma Back to School Summit 2026 Transcript

Seeking Alpha · 9 Sept 2026neutral

Nuvation Bio presented at Citigroup's Biopharma Back to School Summit 2026, and a transcript of the presentation was published on Seeking Alpha. The item reports on the company's participation in the investor conference.

Why it matters — NUVB watchers would care because the presentation transcript offers insight into the company's updates and remarks delivered to the investment community at a major biopharma conference.

Jim Cramer: This Health Care Stock Is Pure Spec, The Only Neocloud I Like Is

Benzinga · 4 Sept 2026negative

On CNBC's "Mad Money Lightning Round," Jim Cramer described Nuvation Bio Inc. (NYSE:NUVB) as a "pure spec." The comment appears in a Benzinga report covering the segment.

Why it matters — A widely followed market commentator publicly labeling NUVB a speculative stock could influence how watchers view the company's risk profile.

FAQ

Frequently asked questions about NUVB stock

What is the NUVB stock price forecast for 2026-2027?

The 10 Wall Street analysts covering Nuvation Bio, Inc. have a median 12-month price target of $13, with estimates ranging from $7 to $21. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is NUVB stock a buy right now?

Of the 10 analysts covering Nuvation Bio, Inc., 9 rate it a Buy, 1 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Nuvation Bio, Inc. 60 out of 100 across roughly 4,600 US stocks as at 18 Sept 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank NUVB?

As at 18 Sept 2026, Nuvation Bio, Inc. ranks 60 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Value (93 of 100).

Will NUVB stock go up?

No one can know that. What the data says: the median 12-month target from 10 analysts implies +113.7% from the last close, and Ticker Nerd's factor model ranks Nuvation Bio, Inc. 60 out of 100 as at 18 Sept 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the NUVB stock forecast for 2030?

No analyst covering Nuvation Bio, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for NUVB are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $7 to $21 over the next 12 months.

How has NUVB stock performed over the past year?

Nuvation Bio, Inc. returned +84.5% over the 12 months to 18 Sept 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Nuvation Bio, Inc. do?

Nuvation Bio Inc. Class A Common Stock represents ownership in Nuvation Bio, a global oncology company focused on developing differentiated therapeutic candidates for difficult-to-treat cancers.

What is the latest news on NUVB?

The most recent item we track (PRNewsWire, 17 Sept 2026): "Nuvation Bio Announces FDA Approval of Supplemental New Drug Application for IBTROZI® (taletrectinib) with Updated Duration of Response in TKI-Naïve Advanced ROS1-Positive Non-Small Cell Lung Cancer". The FDA approved a supplemental New Drug Application for Nuvation Bio's IBTROZI (taletrectinib), updating the label with a nearly 50-month median duration of response in TKI-naïve advanced ROS1-positive non-small cell lung cancer. Approval came about four months ahead of the PDUFA date, with no changes to safety labeling and no new safety signals identified.

Company

About Nuvation Bio, Inc.

Nuvation Bio Inc. Class A Common Stock represents ownership in Nuvation Bio, a global oncology company focused on developing differentiated therapeutic candidates for difficult-to-treat cancers. The company’s current work centers on advancing a portfolio of oncology programs that includes targeted therapies, brain-penetrant inhibitors, and drug-drug conjugate candidates designed to address unmet needs across several cancer types. Its pipeline spans areas such as non-small cell lung cancer, gliomas, and other solid tumors, reflecting a research and development model built around precision medicine and novel mechanisms of action. Nuvation Bio operates as a biopharmaceutical business within the healthcare sector, where it contributes to the broader oncology market through clinical-stage drug development and scientific innovation.

CEO Dr. David T. Hung M.D. · 305 employees · United States · https://www.nuvationbio.com